Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?

被引：1
|
作者：
Rizzo, Alessandro [1 ]
Palmiotti, Gennaro [1 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Struttura Semplice Dipartimentale Oncol Med, Presa Carico Globale Paziente Oncol Don Toni, Viale Orazio Flacco 65, I-70124 Bari, Italy
来源：
IMMUNOTHERAPY | 2022年 / 14卷 / 10期
关键词：
atezolizumab; breast cancer; immune checkpoint inhibitors; immunotherapy; pembrolizumab; triple-negative breast cancer; IMMUNOTHERAPY;
D O I：
10.2217/imt-2022-0021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：755 / 758
页数：4
相关论文
共 50 条
  • [41] Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (11) : 923 - 930
  • [42] Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer
    Elizabeth, Melendez Solano
    Cristina, Stevens Barron Jazmin
    Christian, Chapa Gonzalez
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 431 - 439
  • [43] Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
    Agostinetto, Elisa
    Eiger, Daniel
    Punie, Kevin
    de Azambuja, Evandro
    CURRENT ONCOLOGY REPORTS, 2021, 23 (05)
  • [44] Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
    Elisa Agostinetto
    Daniel Eiger
    Kevin Punie
    Evandro de Azambuja
    Current Oncology Reports, 2021, 23
  • [45] Present and Future of Immunotherapy for Triple-Negative Breast Cancer
    Sriramulu, Sushmitha
    Thoidingjam, Shivani
    Speers, Corey
    Nyati, Shyam
    CANCERS, 2024, 16 (19)
  • [46] Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Gandhi, Shipra
    Slomba, Ronald T.
    Janes, Cayla
    Fitzpatrick, Victoria
    Miller, Janine
    Attwood, Kristopher
    Ioannou, Giorgio
    Ozbey, Sinem
    De Souza, Igor
    Roudko, Vladimir
    Kumar, Prasanna
    Kalathil, Suresh
    Kokolus, Kathleen M.
    Wang, Jianming
    Gomez, Eduardo Cortes
    Takabe, Kazuaki
    Edge, Stephen
    Young, Jessica
    Cappuccino, Helen
    Opyrchal, Mateusz
    O'Connor, Tracey
    Levine, Ellis G.
    Gnjatic, Sacha
    Kalinski, Pawel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (11)
  • [47] Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study
    Karci, Ebru
    Bilici, Ahmet
    Bayram, Buket
    Celayir, Melisa
    Ozyurt, Neslihan
    Uluc, Basak Oyan
    Eken, Aynur
    Basaran, Gul
    Demirci, Umut
    Kemal, Yasemin
    Oruncu, Mehmet Berk
    Olmez, Omer Fatih
    Selcukbiricik, Fatih
    Korkmaz, Taner
    Erturk, Ismail
    Bilgetekin, Irem
    Celik, Serkan
    Turkel, Alper
    Alkan, Ali
    Sakin, Abdullah
    Can, Orcun
    Gunaldi, Meral
    Esin, Ece
    Yildiz, Ozcan
    CANCERS, 2024, 16 (19)
  • [48] Dysfunctional mismatch repair in patients with early triple-negative breast cancer
    Muniz-Castrillo, Maria
    Boluda, Noel Blaya
    Garcia-Torralba, Esmeralda
    Jimenez-Fonseca, Paula
    del Rey, Carmen Gonzalez
    Balbin, Milagros
    Luengo-Gil, Gines
    de la Pena, Francisco Ayala
    Gonzalez, Emilio Esteban
    Carmona-Bayonas, Alberto
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [49] ASO Visual Abstract: Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer
    Myers, Sara P.
    Sevilimedu, Varadan
    Jones, V. Morgan
    Abuhadra, Nour
    Montagna, Giacomo
    Plitas, George
    Morrow, Monica
    Downs-Canner, Stephanie M.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 4950 - 4951
  • [50] Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis
    Mittal, Niti
    Singh, Surjit
    Mittal, Rakesh
    Kaushal, Jyoti
    Kaushal, Vivek
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1754 - +
12345